Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

NCT00267930 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

221

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrial Fibrillation

Interventions

DRUG: Vernakalant (oral)
DRUG: Placebo comparator

Sponsor

Advanz Pharma